Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QMUH | ISIN: US92790C1045 | Ticker-Symbol: 1S1
Tradegate
27.06.25 | 11:51
12,650 Euro
+3,31 % +0,405
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
VIRIDIAN THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
VIRIDIAN THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
12,05012,41027.06.
12,12012,37027.06.

Aktuelle News zur VIRIDIAN THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
20.05.Viridian Therapeutics, Inc.\DE - 8-K, Current Report5
08.05.What 5 Analyst Ratings Have To Say About Viridian Therapeutics7
06.05.Stifel maintains Buy on Viridian Therapeutics, $41 target5
06.05.Viridian Therapeutics, Inc.\DE - 10-Q, Quarterly Report2
06.05.Viridian Therapeutics GAAP EPS of -$0.87 beats by $0.11, revenue of $0.07M beats by $0.03M1
06.05.Viridian Therapeutics, Inc.\DE - 8-K, Current Report-
07.04.Viridian Therapeutics appoints Jeff Ajer to board2
07.04.Viridian Therapeutics, Inc.\DE - 8-K, Current Report1
VIRIDIAN THERAPEUTICS Aktie jetzt für 0€ handeln
04.04.Stifel maintains Buy on Viridian Therapeutics, $41 target3
11.03.Viridian Therapeutics Announces Inducement Stock Option Grants1
10.03.Viridian Therapeutics, Inc.\DE - 8-K, Current Report1
03.03.Viridian Therapeutics, Inc.\DE - S-8, Securities to be offered to employees in employee benefit plans-
03.03.Viridian Therapeutics, Inc.\DE - 10-K, Annual Report-
27.02.Viridian Therapeutics GAAP EPS of -$0.81 beats by $0.24, revenue of $0.07M beats by $0.02M2
27.02.Viridian Therapeutics, Inc.\DE - 8-K, Current Report-
10.01.Viridian Therapeutics, Inc.\DE - 8-K, Current Report-
07.01.Expert Outlook: Viridian Therapeutics Through The Eyes Of 10 Analysts1
12.11.24Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data261WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare...
► Artikel lesen
08.08.24Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results194WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1